Skip to main content
OpenTrials
Completed

NCT Number: NCT02818465

Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemodialyzed Patients

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chu de Reims

Reims, 51092, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Renal impairment
  • Hemodialysis for more than 3 months
  • Have agreed to participate in research
  • Affiliated to a social security scheme
  • major

Exclusion criteria

  • Diabetes , for diabetes induces accelerated formation of advanced glycation end products , which could then be a confounding factor in our study.
  • Protected by law .
  • minors
  • pregnant women
  • Matt or pigmented skin because the skin hyperpigmentation interfere with reading the skin fluorescence giving falsely elevated values .
  • Having an aneurysm of the abdominal aorta known
  • Suffering from a progressive neoplastic disease

Treatment and study plan

Vascular calcifications by Xray

Other

Vascular calcifications by tomodentimetry

Other

Blood sample withdrawn

Biological

Primary outcomes

  1. Frammingham Score

    Time frame: up to 12 months

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Official study title

Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Acronym: RAGE-VASCU

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jun 29, 2016
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.